EUDA Health Holdings Limited (EUDAW) 股票分析

公司概述

EUDA Health Holdings Limited operates primarily as a provider of non-invasive healthcare services, focusing on markets in Singapore, Malaysia, and China. The company's business model centers on offering specialized medical treatments such as bioenergy capsules, stem cell therapy, and CRISPR gene editing services, alongside the sale of supplements and property management services. Although specific sector and industry classifications are not explicitly defined in the available data, the operational scope suggests a focus on the healthcare and wellness segments within the broader financial landscape. The company maintains a workforce of 117 employees, supporting its service delivery across multiple jurisdictions. Regarding its scale, the market capitalization and price-to-book ratio data are currently unavailable, while the reported annual revenue stands at $5.16 million. These financial figures, combined with the employee count, indicate a small-cap enterprise operating with a limited revenue base relative to large-cap peers. The absence of a defined market cap in the provided facts suggests the stock may be trading at a price that does not yet reflect substantial market depth or liquidity, positioning the entity as a micro-cap or small-cap investment vehicle rather than a large-scale industry leader.

财务健康

The company reported a revenue of $5.16 million over the trailing twelve months, yet recorded a net income of $-2,064,341 and an EBITDA of $-1,992,526, revealing a significant structural cost burden that outweighs top-line growth. The substantial gap between the positive revenue of $5.16 million and the negative net income indicates that operating expenses and costs of goods sold are consuming the majority of sales proceeds, resulting in a loss-making operation despite generating sales. Free cash flow is reported at $-3,350,164, which signifies that the company is burning cash through its operations and capital expenditures, thereby limiting its current financial flexibility and reliance on external financing for liquidity needs. Analyzing the margin structure, the gross margin is 22.4%, suggesting that the company retains a modest portion of revenue after direct costs before accounting for overheads. However, the operating margin stands at -37.0% and the profit margin is reported as 5.2%, creating a contradictory picture where the company appears profitable on a profit margin basis but incurs significant losses operationally, which may reflect non-operating income or accounting adjustments. In terms of liquidity and leverage, the company holds $176,584 in cash against a total debt obligation of $2.28 million, resulting in a negative debt-to-equity metric and a price-to-book ratio of -0.01. The current ratio is 0.23, indicating that current assets are only about 23% of current liabilities, which points to severe short-term liquidity constraints and an inability to meet immediate obligations without refinancing or asset liquidation. Return on equity and return on assets metrics are not calculable from the provided data, but the return on assets is listed as -63.9%, which reveals that the company's asset base is generating substantial negative returns and suggests that management has not yet achieved operational efficiency or profitability sufficient to cover asset depreciation and interest costs.

估值评估

The trailing P/E ratio and forward P/E ratio are both unavailable, which implies that traditional valuation based on earnings multiples is not currently applicable given the company's negative earnings position. Consequently, the price-to-book ratio of -0.01 indicates that the market is pricing the company at a negative premium relative to its book value, a metric often seen in distressed or loss-making entities where assets exceed liabilities on a book basis but the stock trades at a discount or negative value. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also unavailable, suggesting that investors must rely on revenue growth and other qualitative factors rather than standard multiple-based comparisons to assess the company's value. The 52-week high and low for the stock are both recorded at $0.03, indicating a compressed trading range where the current price sits at the very bottom of the observed annual range, reflecting significant lack of price appreciation or stability. The beta value is 0.16, which indicates that the stock's price volatility is substantially lower than the broader market, suggesting low correlation with general market movements and potentially lower risk in terms of systemic market fluctuations.

Growth & Income

Revenue growth is reported at 60.2% year-over-year, demonstrating aggressive top-line expansion, while earnings growth is unavailable due to the negative earnings profile. The divergence between high revenue growth and negative earnings suggests that the company is prioritizing market share acquisition or service scaling over immediate profitability, a common strategy in early-stage biotech or healthcare service providers. Since the company does not pay dividends, as indicated by the unavailable dividend yield and payout ratio, it retains all earnings to reinvest into operations, research, or debt reduction rather than distributing cash to shareholders. The overall growth and income profile is characterized by strong revenue expansion offset by significant cash burn, with no current income generation for investors. This profile implies that the company is in a high-growth, pre-profitability phase where capital efficiency remains a critical challenge for long-term sustainability.